Novo Nordisk Downgraded to Sell Amidst 70% Stock Slide From Peak
Deutsche Bank has downgraded Novo Nordisk (NVO) to a "Sell" rating, citing concerns over growth prospects and recent trial setbacks, adding pressure to shares already down 70% from their 2024 peak.
The short version
- Deutsche Bank downgraded Novo Nordisk (NYSE: NVO) to "Sell" from "Hold" on Thursday, August 27, 2026, lowering its price target by 9% to 265 Danish kroner (DKK).
- Analyst Emmanuel Papadakis cited disappointing Ziltivekimab trial results and limited growth prospects for Wegovy among reasons for the downgrade.
- Novo Nordisk's stock has plummeted approximately 70% from its June 2024 peak, with shares falling 2-3% immediately after the downgrade announcement.
- The downgrade follows earlier challenges in 2026, including a 14.64% stock drop in February after management forecasted slower growth for the year.
- Despite the downgrade, 62% of analysts, according to FactSet, were still advising investors to "Hold" the stock as of August 27, 2026.
Novo Nordisk (NYSE: NVO), the pharmaceutical giant behind popular weight-loss drugs like Ozempic and Wegovy, saw its shares dip further on Thursday, August 27, 2026, after Deutsche Bank downgraded the stock to a "Sell" rating from "Hold." This move intensified scrutiny on the company's future growth trajectory, particularly as its stock has already experienced a significant 70% slide from its peak in June 2024.
Deutsche Bank analyst Emmanuel Papadakis initiated the downgrade, also cutting Novo Nordisk's price target by 9% to 265 Danish kroner (DKK) from the previous 290 DKK. The decision sent Novo shares (DK:NOVO.B) down more than 3% in Copenhagen trading, closing at 304.95 kroner, while its U.S. shares (NVO) declined about 2% to $46.15 in early trading.
Why did Deutsche Bank downgrade Novo Nordisk?
The downgrade primarily stems from Deutsche Bank's concerns regarding Novo Nordisk's growth prospects, according to analyst Emmanuel Papadakis. A significant factor was the disappointing results from the Ziltivekimab trial, an anti-inflammatory drug that failed to reduce the risk of major adverse cardiovascular events in a late-stage study and is now considered "effectively out of the picture."
Additionally, Papadakis pointed to anticipated "bump" in weight-loss drug sales from Medicare covering Wegovy for cardiovascular patients as "looking limited." Persisting concerns about a return to meaningful growth in 2027 and a "large patent cliff problem" further out also weighed on the rating. The analyst noted "mixed" second-quarter earnings earlier in August, which included a narrow sales miss for the new Wegovy pill, with sales reaching 3.22 billion Danish crowns ($497 million) against an expected 3.3 billion crowns, and a trial setback for CagriSema.
What is the broader analyst sentiment?
Despite Deutsche Bank's bearish stance, the broader analyst sentiment on Novo Nordisk remained largely cautious but not outright negative. As of August 27, 2026, FactSet data indicated that 62% of analysts were still advising investors to "Hold" the stock, with 26% rating it a "Buy." Only three other analysts had an "Underweight" or "Sell" rating. LSEG data further showed that out of 33 analysts, eight rated "Strong Buy" or "Buy," 23 "Hold," and two "Strong Sell" or "Sell," reflecting a prevailing "Hold" consensus rating on Wall Street based on five "Holds" issued over the past three months.
What challenges has Novo Nordisk faced recently?
Novo Nordisk has navigated a challenging year leading up to this downgrade. On February 3, 2026, the company's stock price plummeted 14.64% after management forecasted slower growth for the year. This was attributed to US price pressure, increased competition, and patent/product mix headwinds, with the company predicting sales for 2026 would fall between 5% and 13%, ending years of double-digit gains.
The recent 70% drop from its June 2024 peak, as reported by Simply Wall St. showing a 49% fall over the past three years for shareholders, underscores a period of sustained pressure. However, the company did offer a glimmer of optimism in August 2026 when it raised its full-year sales and profit outlook for 2026, narrowing the expected sales decline to 0-6% from a previous range of 4-12%, suggesting some stabilization despite ongoing headwinds.
Frequently asked questions
When did Deutsche Bank downgrade Novo Nordisk?
Deutsche Bank downgraded Novo Nordisk (NYSE: NVO) to a "Sell" rating from "Hold" on Thursday, August 27, 2026.
What were the primary reasons for the downgrade?
The primary reasons cited by analyst Emmanuel Papadakis included disappointing results from the Ziltivekimab trial, limited growth prospects for Wegovy sales to cardiovascular patients, a future "large patent cliff problem," and mixed second-quarter earnings.
Reported by the RevReck Newsroom from the reporting linked below, with AI assistance in drafting, under editorial rules covering accuracy, attribution and what we will not publish. Read our editorial standards, or email corrections to operations@revreck.com.